Purpose: The aim of this study was to determine whether a preservative (0.005% benzalkonium chloride [BAK]) enhances the antibacterial efficacy of an antibiotic (0.3% gatifloxacin, [GAT]) in vivo.
Methods: Rabbits were inoculated intrastromally with GAT-resistant, methicillin-resistant Staphylococcus aureus or Staphylococcus epidermidis and then divided into four treatment groups: 0.3% GAT + 0.005% BAK; 0.3% GAT without BAK; vehicle including 0.005% BAK; and saline control. At 4 h postinoculation, topical treatment was initiated in both eyes every 15 min for 5 h. One (1) h after therapy, corneal colony counts were determined.
Results: For S. aureus, duplicate experiments demonstrated that GAT + BAK and GAT without BAK significantly reduced colony counts, compared with BAK or saline (P < 0.05). Further, GAT + BAK significantly reduced colony counts, compared with GAT without BAK. BAK alone was equivalent to the saline control. For S. epidermidis, duplicate experiments demonstrated that GAT + BAK and GAT without BAK significantly reduced colony counts, compared with BAK or saline (P < 0.05). There were no differences between GAT + BAK and GAT without BAK for S. epidermidis.
Conclusions: For the first time, we demonstrated that a preservative (0.005% BAK) significantly enhanced the antibacterial efficacy of an antibiotic (0.3% GAT) in an experimental rabbit model of intrastromal keratitis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1089/jop.2008.0017 | DOI Listing |
J Ocul Pharmacol Ther
August 2008
The Charles T. Campbell Ophthalmic Microbiology Laboratory, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.
Purpose: The aim of this study was to determine whether a preservative (0.005% benzalkonium chloride [BAK]) enhances the antibacterial efficacy of an antibiotic (0.3% gatifloxacin, [GAT]) in vivo.
View Article and Find Full Text PDFAm J Ophthalmol
November 2006
Charles T. Campbell Ophthalmic Microbiology Laboratory at the University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Purpose: Varied concentrations of moxifloxacin (MOX) and gatifloxacin (GAT) and the addition of 0.005% benzalkonium chloride (BAK) were evaluated for eliminating Staphylococcus aureus (SA), Pseudomonas aeruginosa (PA), and coagulase-negative Staphylococcus (CNS).
Design: In vitro laboratory investigation.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!